CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
12.02
+0.10 (0.84%)
At close: Dec 19, 2025, 4:00 PM EST
12.00
-0.02 (-0.17%)
After-hours: Dec 19, 2025, 7:52 PM EST
CorMedix Revenue
CorMedix had revenue of $104.28M in the quarter ending September 30, 2025, with 810.22% growth. This brings the company's revenue in the last twelve months to $211.57M, up 1,625.42% year-over-year. In the year 2024, CorMedix had annual revenue of $43.47M.
Revenue (ttm)
$211.57M
Revenue Growth
+1,625.42%
P/S Ratio
3.80
Revenue / Employee
$3,296,980
Employees
65
Market Cap
947.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | 283.27K | -146.53K | -34.09% |
| Dec 31, 2018 | 429.80K | 100.47K | 30.51% |
| Dec 31, 2017 | 329.33K | 105.22K | 46.95% |
| Dec 31, 2016 | 224.11K | 13.98K | 6.65% |
| Dec 31, 2015 | 210.13K | 20.86K | 11.02% |
| Dec 31, 2014 | 189.27K | 187.27K | 9,358.97% |
| Dec 31, 2013 | 2.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRMD News
- 3 days ago - CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath - GlobeNewsWire
- 5 weeks ago - CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating - Seeking Alpha
- 5 weeks ago - Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations - Benzinga
- 5 weeks ago - CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance - GlobeNewsWire
- 7 weeks ago - CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 - GlobeNewsWire
- 2 months ago - CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings - Seeking Alpha